How Obamacare is changing corporate strategy

ON HEALTH

clock • 2 min read

President Obama's plans for universal healthcare have been pivotal in driving sector returns over the last year, explains Polar Capital managers Gareth Powell (pictured) and Dan Mahoney.

The healthcare sector has performed extremely well year-to-date, with the biotechnology space being the real highlight. Positive newsflow has continued to show the fundamental improvement across healthcare, which has driven outperformance.  The potential for improving growth rates across the industry on a forward-looking basis should drive increased interest from investors.    We believe valuations on healthcare stocks remain attractive across pharmaceuticals, biotechnology, medical devices and healthcare services, when considered on an absolute, relative and historical metrics. ...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot